DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

NCT03361098 on ClinicalTrials.gov · last registry update 2021-06-11

Finished 25 November 2019, after enrolling 65 people. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Amsterdam UMC, location VUmc
Sponsor type: Other
Enrollment: 65
Started: 2017-09-18
Primary completion: 2019-11-25 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Differences in neuronal activity in the central reward and satiety circuits in response to food-related stimuli by BOLD fMRI signal

Conditions studied

Type 2 Diabetes Mellitus · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.